pharma · Dermatitis atopic · Cancer
Sanofi-Aventis U.S
Sanofi-aventis Healthcare Pty Ltd
Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater, USA
- Employees
- 177
- Programs
- 117
- Drugs
- 148
- Patents
- 0
EFC17236
Phase 3 · small molecule · Polyneuropathy, Inflammatory Demyelinating, Chronic
EFC17236 for Polyneuropathy, Inflammatory Demyelinating, Chronic is a Phase 3 program (small_molecule) at Sanofi-aventis Healthcare Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code EFC17236
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi-aventis Healthcare Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- Status
- active
- Trials
- 1